Precedential Federal Circuit Opinions
1.
FOREST LABORATORIES, LLC v. SIGMAPHARM
LABORATORIES, LLC [OPINION - PRECEDENTIAL] (2017-2369,
2017-2370, 2017-2372, 2017-2373, 2017-2374, 2017-2375, 2017-2376,
2017-2389, 2017-2412, 2017-2436, 2017-2438, 2017-2440, 2017-2441,
03/14/2019) (PROST, DYKE, MOORE)
Moore, J. Vacating and remanding the district court's
determinations regarding validity and infringement issues.
This appeal involves multiple Abbreviated New Drug Applications
(ANDAs) filed with the Food and Drug Administration by companies
seeking to market generic versions of Saphris, a drug product
administered sublingually (i.e., dissolved under the tongue).
Regarding the validity issue, the Court remanded for the district
court to make an express finding regarding one of the
defendants' proposed motivations to combine prior art
references that allegedly rendered the claims invalid as
obvious. The Court also affirmed the district